Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.8 billion in 66 countries. Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Type
Public
HQ
Darmstadt, DE
Size (employees)
52,834 (est)+3%
Merck KGaA is headquartered in Darmstadt, DE
Report incorrect company information

Key People/Management at Merck KGaA

Stefan Oschmann

Stefan Oschmann

Chairman of the Executive Board | CEO
Udit Batra

Udit Batra

Member of the Executive Board | CEO Life Science
Kai Beckmann

Kai Beckmann

Member of the Executive Board | CEO Performance Materials
Walter Galinat

Walter Galinat

Member of the Executive Board
Belén Garijo

Belén Garijo

Member of the Executive Board | CEO Healthcare
Marcus Kuhnert

Marcus Kuhnert

Member of the Executive Board | Chief Financial Officer

Merck KGaA Office Locations

Merck KGaA has an office in Darmstadt
Darmstadt, DE (HQ)
250 Frankfurter Str.
Show all (1)
Report incorrect company information

Merck KGaA Financials and Metrics

Merck KGaA Financials

Merck KGaA's revenue was reported to be €12.84 b in FY, 2015 which is a 13% increase from the previous period.
EUR

Revenue (FY, 2015)

12.8 b

Revenue growth (FY, 2014 - FY, 2015), %

13%

Gross profit (FY, 2015)

8.8 b

Gross profit margin (FY, 2015), %

68.3%

Net income (FY, 2015)

1.1 b

EBIT (FY, 2015)

1.8 b

Market capitalization (30-Oct-2017)

40 b

Closing share price (30-Oct-2017)

91.8

Cash (31-Dec-2015)

832.2 m

EV

48.7 b
Merck KGaA's current market capitalization is €40 b.
EURFY, 2014FY, 2015

Revenue

11.4 b12.8 b

Revenue growth, %

13%

Cost of goods sold

3.5 b4.1 b

Gross profit

7.8 b8.8 b
eurY, 2014Y, 2015

Cash

2.9 b832.2 m

Total Assets

26 b38 b

Total Debt

3.6 b9.6 b

Total Liabilities

14.2 b25.2 b
EURFY, 2014FY, 2015

Cash From Operating Activities

2.7 b2.2 b
EURY, 2015

EV/EBIT

26.4 x

EV/CFO

22.2 x
Show all financial metrics
Report incorrect company information

Merck KGaA News and Updates

BRIEF-P&G Acquires the Consumer Health Business Of Merck KGaA, Darmstadt, Germany

* ACQUIRES THE CONSUMER HEALTH BUSINESS OF MERCK KGAA, DARMSTADT, GERMANY

BRIEF-P&G Nears Deal To Acquire Merck KGaA's Consumer-Health Unit - WSJ

* P&G NEARS DEAL TO ACQUIRE MERCK KGAA’S CONSUMER-HEALTH UNIT - WSJ, CITING SOURCES Source text: https://on.wsj.com/2qHVGJh Further company coverage:

Flow Cytometer Reagents Market 2018 Highlights | Phenomenal Growth of 12% with Biocompare, Miltenyi Biotec, Merck KGaA, ImmunoReagents Inc | Forecast to 2023

Flow Cytometer Reagents Market Provide Country Level Analysis of the Market with Respect to the Current Market Size and Future Prospective. Posted via Industry Today. Follow us on Twitter @IndustryToday

FiercePharmaAsia—More Takeda deals, China’s pharma supply issues, Merck KGaA expansion

Takeda made R&D deals in neurological disorders and with academic institutes, China's crackdown on pollution has caused some supply issues for the pharma industry, Merck KGaA plans further manufacturing expansions in Asia, and more.
Show more
Report incorrect company information